Anti-Cytokine Biotherapies and Inflammatory Joint Diseases
PDF

Keywords

TNF
IL-6
IL-17
Biotherapies
Infections
Drug safety

Categories

How to Cite

1.
Miossec P. Anti-Cytokine Biotherapies and Inflammatory Joint Diseases. Integr J Med Sci [Internet]. 2017 May 3 [cited 2022 Oct. 5];4:51-4. Available from: https://www.mbmj.org/index.php/ijms/article/view/57

Abstract

Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis represent the most frequent inflammatory arthritis where the three cytokines TNF, IL-6, and IL-17 contribute to the clinical expression and the consequences on a joint structure. Each cytokine has a specific mode of action that explains differences in therapeutic indications. TNF inhibitors showed impressive clinical results first in rheumatoid arthritis. These results were then extended to psoriatic arthritis, and ankylosing spondylitis.
IL-6 inhibitors are registered only for rheumatoid arthritis and those of IL-17 for psoriatic arthritis, and ankylosing spondylitis. The wider use of these new molecules has required the definition of recommendations to better define their field of action and to prevent their side effects, first from infections.

https://doi.org/10.15342/ijms.v4is.141
PDF

References

Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001; 19:163-196. https://doi.org/10.1146/annurev.immunol.19.1.163

Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010 May, 22:347-52. https://doi.org/10.1093/intimm/dxq030

Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends Mol Med. 2016 Mar; 22(3):230-241. https://doi.org/10.1016/j.molmed.2016.01.001

Miossec P. Interleukine 17 et l'inflammation chronique : de la découverte au ciblage thérapeutique. Bull Acad Natle Méd. Apr- May 2016; 200(4-5): 933-942. https://doi.org/10.1016/S0001-4079(19)30685-5

Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 200 Jun; 44(6):1293-303. https://doi.org/10.1002/1529-0131(200106)44:6%3C1293::aid-art221%3E3.0.co;2-t

Osta B, Roux JP, Lavocat F, Pierre M, Ndongo-Thiam N, et al. Differential Effects of IL-17A and TNF-alpha on Osteoblastic Differentiation of Isolated Synoviocytes and on Bone Explants from Arthritis Patients. Front Immunol. 2015 Apr; 6:151. https://doi.org/10.3389/fimmu.2015.00151

Osta B, Benedetti G, Miossec P. Classical and Paradoxical Effects of TNF-alpha on Bone Homeostasis. Front Immunol. 2014 Feb 13; 5:48. https://doi.org/10.3389/fimmu.2014.00048

Hot A, Lenief V, Miossec P. Combination of IL-17 and TNFalpha induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis. 2012 May; 71(5):768-76. https://doi.org/10.1136/annrheumdis-2011-200468

Maini RN, St Clair EW, Breedveld FC, Furst D, Kalden JR, Weisman M, et al: Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4; 354(9194):1932-9. https://doi.org/10.1016/s0140-6736(99)05246-0

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in Patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28; 340(4):253-9. https://doi.org/10.1056/nejm199901283400401

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30; 343(22):1586-93. https://doi.org/10.1056/nejm200011303432201

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16; 130(6):478-86. https://doi.org/10.7326/0003-4819-130-6-199903160-00004

Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 2015 Jan, 27(1):21-29. https://doi.org/10.1093/intimm/dxu081

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24, 373(26):2534-48. https://doi.org/10.1056/nejmoa1505066

Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11, 345(15):1098-1104. https://doi.org/10.1056/nejmoa011110

Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum. 1997 Dec; 40(12):2105-15. https://doi.org/10.1002/art.1780401203

Toh ML, Kawashima M, Hot A, Miossec P, Miossec P. Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis. 2010 Aug; 69(8):1562-7. https://doi.org/10.1136/ard.2009.111757

Kawashima M, Miossec P. mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J Clin Immunol. 2005 May; 25(3):209-214. https://doi.org/10.1007/s10875-005-4092-4

Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009 Aug 27; 361(9):888-98. https://doi.org/10.1056/nejmra0707449

Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011 Apr 1; 332(6025): 65-8. https://doi.org/10.1126/science.1200439

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2017 Pierre Miossec

Downloads

Download data is not yet available.